Pancreatic cancer, the hope of a vaccine to prevent it: the study and the first tests
Adnkronos - Authors call it "the first demonstration on the man that a vaccine targeted at Kras can safely generate lasting immune responses
- Center-right1
- Agency2
2 agency rewrites / co-publications detected
Summary
Adnkronos - Authors call it "the first demonstration on man that a vaccine targeted at Kras can safely generate lasting immune responses, potentially preventing the development of cancer in people at risk". In a 16.5-month median follow-up, none of the participants developed a pancreatic tumor or a high-risk pancreatic lesion requiring surgical removal.". In Phase 1, the first step of clinical trial ister, the vaccine candidate "has stimulated specific T-cell responses for Kras in 90% of participants".
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
Adnkronos - Authors call it "the first demonstration on man that a vaccine targeted at Kras can safely generate lasting immune responses, potentially preventing the development of cancer in people at risk"
reliability low1/2 sources
Reported detailssecondary facts, each attributed to its source
In a 16.5-month median follow-up, none of the participants developed a pancreatic tumor or a high-risk pancreatic lesion requiring surgical removal.".
according to Il TempoIn Phase 1, the first step of clinical trial ister, the vaccine candidate "has stimulated specific T-cell responses for Kras in 90% of participants".
according to Il Tempo
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
Adnkronos - Authors call it "the first demonstration on the man that a vaccine targeted at Kras can safely generate answers..
omitted byRight sidecovered byPublic / Agencies
Sources2 sources cross-checked
Center-right1
Agency1
